| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6372252 | RB HLTH | Guaifenesin sustained release formulation and tablets |
Apr, 2020
(4 years ago) | |
| US6955821 | RB HLTH | Sustained release formulations of guaifenesin and additional drug ingredients |
Apr, 2020
(4 years ago) | |
| US7838032 | RB HLTH | Sustained release of guaifenesin |
Apr, 2020
(4 years ago) | |
Mucinex is owned by Rb Hlth.
Mucinex contains Guaifenesin.
Mucinex has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mucinex are:
- US6372252
- US6955821
- US7838032
Mucinex was authorised for market use on 18 December, 2002.
Mucinex is available in tablet, extended release;oral dosage forms.
Mucinex can be used as expectorant.
The generics of Mucinex are possible to be released after 28 April, 2020.
Drugs and Companies using GUAIFENESIN ingredient
Market Authorisation Date: 18 December, 2002
Treatment: Expectorant
Dosage: TABLET, EXTENDED RELEASE;ORAL
How can I launch a generic of MUCINEX before it's drug patent expiration?
More Information on Dosage
MUCINEX family patents
